The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer

Jm, Niloff; Knapp, RC; Lavin, PT

doi:10.1016/0020-7292(87)90197-4

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor size in the recurrent cases with normal CA125 level was less than 2 cm in diameter. Niloff et al reported that the titer of CA125 became elevated before clinical recurrence in 94% of the cases with a median lead time of 3 months (24) . Makar et al reported that the CA125 level at the time of relapse was a significant predictor of survival.…”

Section: Discussionmentioning

confidence: 99%

Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer

Murakami¹,

Miyamoto²,

Iida³

et al. 2006

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

We evaluated the clinical role of the combination of positron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) and tumor marker CA125, in the detection of recurrence after initial therapy for epithelial ovarian cancer. The indication is the cases that cannot be confirmed the recurrence by conventional imaging modalities. Ninety patients underwent PET and computed tomography, including the measurement of specific tumor markers. FDG-PET confirmed recurrence in 46 patients (51%), and the recurrent site was confirmed by PET alone in 17 (37%). PET had high sensitivity for detecting both intraperitoneal and retroperitoneal metastases (93.9 and 92.9%, respectively). PET imaging was able to detect normal-sized metastases in the lymph nodes in 14 (50%) of the 28 patients with retroperitoneal metastasis. PET could show 87.5% positive rate of recurrent patients with asymptomatic rise of CA125 who had no sign of recurrence by conventional imaging methods. Of the 46 recurrent patients, 41 (89%) had specific elevated titers of CA125 at the first treatment. PET imaging was able to detect recurrence at relatively low titers (a median 68 U/mL) of CA125. In 8 (19.5%) of these 41 patients, recurrence with normal CA125 levels could be confirmed only by PET. The sensitivity of the combination of PET and CA125 was 97.8% with only one false-negative case. The combination of FDG-PET and CA125 titer is useful for the accurate detection of recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer

Murakami¹,

Miyamoto²,

Iida³

et al. 2006

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…Among women relapsing at follow‐up after treatment of ovarian cancer, serum CA 125 levels may rise prior to evidence of recurrent disease being detected through imaging methods (16) . At second look surgery CA 125 levels may be elevated, but only microscopic deposits of disease are present (17,18) . It is not surprising that in the preclinical phase of this disease that an analogous situation should exist in some cases.…”

Section: Discussionmentioning

confidence: 99%

Ovarian cancer identified through screening with serum markers but not by pelvic imaging

Woolas¹,

Oram²,

Jeyarajah³

et al. 1999

Int J Gynecol Cancer

View full text Add to dashboard Cite

Woolas RP, Oram DH, Jeyarajah AR, Bast RC Jr, Jacobs IJ. Ovarian cancer identified through screening with serum markers but not by pelvic imaging. This study evaluated the possible role of 3 additional tumor markers to CA 125 among postmenopausal volunteers participating in a sequential multimodal ovarian cancer screening study. In 82 asymptomatic women the finding of a serum CA 125 level of > 30 U/ml precipitated pelvic ultrasound examination. Levels of CA15-3, CA72-4 and CA19-9 were subsequently determined in sera stored from the time of the CA 125 assay. Following ultrasound 29 women underwent surgery for benign conditions. The remaining 53 women underwent 2 years of surveillance. In 5 of these women a diagnosis of ovarian cancer was established between 6 and 10 months after their initial investigation. Elevated levels of at least one of the 3 additional tumor markers were present in the serum, prior to ultrasound abnormalities being detected, in 4 (80%) of the women who developed cancer. At least one of this 3-marker panel was elevated in 29% of the 48 women who have not developed cancer and 14% of the 29 women undergoing surgery for benign conditions. Information complementary to pelvic ultrasound examination for the preclinical detection of ovarian cancer could be obtained through multiple marker assay. Coordinated elevated serum levels of tumor markers could increase the sensitivity of this sequential screening protocol.

show abstract

“…Currently, serum CA‐125 level is the marker for the clinical management of ovarian cancer patients: on one hand, the changes in antigen levels during early chemotherapy have been found to correlate with the possibility of achieving a pathologic complete response and with the overall survival of the patients (8–10). On the other hand, an increase in CA‐125 levels during the follow‐up period is a known marker for recurrence of disease (11), (12). Moreover, recently the preoperative determination of CA‐125 has been used for the discrimination between benign and malignant pelvic tumor mass (13).…”

mentioning

confidence: 99%

COX‐2 and preoperative CA‐125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer

Raspollini

Amunni

Villanucci

et al. 2006

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer

Cited by 5 publications

References 0 publications

Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer

Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer

Ovarian cancer identified through screening with serum markers but not by pelvic imaging

COX‐2 and preoperative CA‐125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer

Contact Info

Product

Resources

About